Quince Therapeutics, Inc. Total Long-Term Debt
Quince Therapeutics, Inc. (QNCX) had Total Long-Term Debt of $0 as of 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-04-10
- 2025-12-31: Long-term Debt $0.00.
- 2025-09-30: Long-term Debt $0.00.
- 2025-06-30: Long-term Debt $16.99M.
- 2025-03-31: Long-term Debt $15.27M.
| Period end | Long-term Debt |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-10 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $16.99M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $15.27M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $14.32M 10-K · filed 2026-04-10 |
| 2024-09-30 | $14.90M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $13.83M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $13.52M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $13.43M 10-K · filed 2025-03-24 |
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |